Ann: Imugene First Patient Dosed in PD1-VAXX Clinical Trial, page-18

I've not seen anyone claiming an instant Disallowed, although the sentiment is perhaps overly bullish (IMO only) for where IMU is in the process. That being said, what's not appealing about this company at the moment? Very good financial health, due soon for a rebate, quite an extensive and diversified pipeline, solid leadership, etc. Price no doubt also incorporates the prospect (still far off IMO only) of a takeover in the medium-term.

In short, if the results so far hold IMU doesn't just have one proprietary innovation, but numerous and a clear path to realization. There will, of course, be dips and sways but I haven't seen anything to suggest any significant reversal... Have you?

Also strange to use the term 'sucked in' with an avatar of what looks like Daniel Andrews in front of Mao and Deng...